NCT06672822View on ClinicalTrials.gov

Intralesional Injection of STS in Treatment of Calcinosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

May 1, 2029

Conditions
Systemic Sclerosis (SSc)DermatomyositisMixed Connective Tissue Disease (MCTD)Calcinosis
Interventions
DRUG

Sodium Thiosulfate (STS)

Depending on the size of the calcinosis lesion, 1-5ml of STS (250mg/ml) will be used for injection under ultrasound guidance.

Trial Locations (1)

15213

RECRUITING

UPMC Arthritis and Autoimmunity Center, Pittsburgh

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Robyn T. Domsic, MD, MPH

OTHER